Astellas Pharma Inc 2010 AR2
The report outlines Astellas Pharma Inc.'s financial and operational performance for the fiscal year ended March 31, 2010, alongside its strategic mid-term management plan (MTP14) for FY2010-2014. Key highlights include the launch of MTP14 with the slogan 'Leveraging our strengths to grow,' focusing on urology, transplantation, and oncology as core therapeutic areas. The company completed the acquisition of OSI Pharmaceuticals in June 2010 to accelerate its oncology franchise. Additionally, the report introduces Astellas' CSR-based management framework, which covers compliance, environment, society, employees, and economy.
Company: Astellas Pharma Inc
Sector: Manufacturing
Country: Japan
Year: 2010
Type: AR2
Pages: 82
Back to company
Astellas Pharma Inc
Annual Report
The report outlines Astellas Pharma Inc.'s financial and operational performance for the fiscal year ended March 31, 2010, alongside its strategic mid-term management plan (MTP14) for FY2010-2014. Key highlights include the launch of MTP14 with the slogan 'Leveraging our strengths to grow,' focusing on urology, transplantation, and oncology as core therapeutic areas. The company completed the acquisition of OSI Pharmaceuticals in June 2010 to accelerate its oncology franchise. Additionally, the report introduces Astellas' CSR-based management framework, which covers compliance, environment, society, employees, and economy.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2010
Reporting Period
Apr 1, 2009 - Mar 31, 2010
Fiscal Year
2010
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees